Safety of regular formoterol or salmeterol in children with asthma: An overview of Cochrane reviews

Cochrane Database of Systematic Reviews

Volumn 2012, Issue 10, 2012, Pages

  Cates, Christopher J ^a   Oleszczuk, Marta ^b   Stovold, Elizabeth ^a   Wieland, L Susan ^c  

^a ST GEORGE S HOSPITAL   (United Kingdom)

^b UNIVERSITY OF ALBERTA   (Canada)

^c BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FORMOTEROL; PLACEBO; SALMETEROL; ANTIASTHMATIC AGENT; DRUG DERIVATIVE; ETHANOLAMINE DERIVATIVE; SALBUTAMOL;

ALL CAUSE MORTALITY; ASTHMA; CHILD; DRUG SAFETY; HUMAN; META ANALYSIS; MONOTHERAPY; OUTCOME ASSESSMENT; PEDIATRICS; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW; DRUG COMBINATION; LITERATURE; METHODOLOGY; MORTALITY; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ALBUTEROL; ANTI-ASTHMATIC AGENTS; ASTHMA; CHILD; DRUG THERAPY, COMBINATION; ETHANOLAMINES; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REVIEW LITERATURE AS TOPIC;

EID: 84873317147     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD010005.pub2     Document Type: Review

References (44)

1. Cates Christopher J, Cates Matthew J. Regular treatment with salmeterol for chronic asthma: serious adverse events. Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd, 2008, issue 3. [DOI: 10.1002/14651858.CD006363.pub2; : CD006363]
2. Cates CJ, Lasserson TJ, Jaeschke R. Regular treatment with salmeterol and inhaled steroids for chronic asthma: serious adverse events. Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd, 2009, issue 3. [DOI: 10.1002/14651858.CD006922.pub2]
3. Cates CJ, Lasserson TJ, Jaeschke R. Regular treatment with formoterol and inhaled steroids for chronic asthma: serious adverse events. Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd, 2009, issue 2. [DOI: 10.1002/14651858.CD006924.pub2]
4. Cates Christopher J, Lasserson Toby J. Regular treatment with formoterol and an inhaled corticosteroid versus regular treatment with salmeterol and an inhaled corticosteroid for chronic asthma: serious adverse events. Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd, 2010, issue 1. [DOI: 10.1002/14651858.CD007694.pub2; : CD007694]
5. Cates CJ, Cates MJ. Regular treatment with formoterol for chronic asthma: serious adverse events. Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd, 2012, issue 4. [DOI: 10.1002/14651858.CD006923.pub3]
6. Cates CJ, LJ . Regular treatment with formoterol versus regular treatment with salmeterol for chronic asthma: serious adverse events. Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd, 2012, issue 3. [DOI: 10.1002/14651858.CD007695.pub3]
7. Altman DG, Bland JM. Statistics Notes: Interaction revisited: the difference between two estimates. BMJ 2003;326(7382):219.
8. Anderson GP. Endotyping asthma: new insights into key pathogenic mechanisms in a complex, heterogeneous disease. Lancet 2008;372(9643):1107-19.
9. Boushey HA, Holtzman MJ, Sheller JR, Nadel JA. Bronchial hyperreactivity. American Review of Respiratory Disease 1980;121(2):389-413.
10. Bradburn MJ, Deeks JJ, Berlin JA, Russell Localio A. Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events. Statistics in Medicine 2007;26(1):53-77.
11. Bucher HC, Guyatt GH, Griffith LE, Walter SD. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. Journal of Clinical Epidemiology 1997;50(6):683-91.
12. Castle W, Fuller R, Hall J, Palmer J. Serevent nationwide surveillance study: comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment. BMJ 1993;306(6884):1034-7.
13. Cates CJ. Safety of tiotropium. BMJ 2011;342:d2970.
14. Chan A-W, Hrobjartsson A, Haahr MT, Gotzsche PC, Altman DG. Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles. JAMA 2004;291(20):2457-65.
15. Chan A-W, Krleza-Jeric K, Schmid I, Altman DG. Outcome reporting bias in randomized trials funded by the Canadian Institutes of Health Research. Canadian Medical Association Journal 2004;171(7):735-40.
16. Chowdhury BA, Seymour SM, Levenson MS. Assessing the safety of adding LABAs to inhaled corticosteroids for treating asthma. The New England Journal of Medicine 2011;364(26):2473-5.
17. Cockcroft D. Airway hyper-responsiveness as a determinant of the early asthmatic response to inhaled allergen. Journal of Asthma 2006;43(3):175-8.
18. Ducharme Francine M, Ni Chroinin M, Greenstone I, Lasserson Toby J. Addition of long-acting beta2-agonists to inhaled corticosteroids versus same dose inhaled corticosteroids for chronic asthma in adults and children. Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd, 2010, issue 5. [DOI: 10.1002/14651858.CD005535.pub2]
19. Ducharme Francine M, Lasserson Toby J, Cates Christopher J. Addition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthma. Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd, 2011, issue 5. [DOI: 10.1002/14651858.CD003137.pub4]
20. Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention. Available from: http://www.ginasthma.org/. 2011.
21. Expert Working Group (Efficacy) of the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). Clinical safety data management: definitions and standards for expedited reporting. www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM073087.pdf (accessed July 2012). 1995.
22. Ioannidis JP, Lau J. Completeness of safety reporting in randomized trials: an evaluation of 7 medical areas. JAMA 2001;285(4):437-43.
23. Ioannidis JPA, Evans SJW, Gotzsche PC, O'Neill RT, Altman DG, Schulz K, et al.CONSORT Group. Better reporting of harms in randomized trials: an extension of the CONSORT statement. Annals of Internal Medicine 2004;141(10):781-8.
24. Li JS, Qaqundah PY, Weinstein SF, LaForce CF, Ellsworth AV, Ortega HG, et al.Fluticasone propionate/salmeterol combination in children with asthma: Key cardiac and overall safety results. Clinical Research and Regulatory Affairs 2010;27(3):87-95.
25. Lougheed MD, Lemiere C, Dell SD, Ducharme FM, Fitzgerald JM, Leigh R, et al.Canadian Thoracic Society Asthma Committee commentary on long-acting beta-2 agonist use for asthma in Canada. Canadian Respiratory Journal 2010;17(2):57-58.
26. McMahon AW, Levenson MS, McEvoy BW, Mosholder AD, Murphy D. Age and risks of FDA-approved long-acting β2-adrenergic receptor agonists. Pediatrics 2011;128(5):e1147-54.
27. GlaxoSmithKline . A Randomized, Double-Blind, Parallel Group Study of FSC 100/50 and FP 100, both twice daily, in a Pediatric Population during the Fall Viral Season [ADA113872]. http://www.gsk-clinicalstudyregister.com/.
28. AstraZeneca . A 6 Month Safety Study Comparing Symbicort With Inhaled Corticosteroid Only in Asthmatic Adults and Adolescents. ClinicalTrials.gov 2012 (accessed June 2012).
29. GlaxoSmithKline . 6-month Safety and Benefit Study of ADVAIR in Children 4-11 Years Old (VESTRI). ClinicalTrials.gov 2012 (accessed 29/06/2012).
30. Merck . A Serious Asthma Outcome Study With Mometasone Furoate/Formoterol Versus Mometasone Furoate in Asthmatics 12 Years and Over (P06241 AM3) (SPIRO). ClinicalTrials.gov 2012 (accessed June 2012).
31. GlaxoSmithKline . SAS115359: A 6-month Study to Assess the Safety and Benefit of Inhaled Fluticasone Propionate/Salmeterol Combination Compared With Inhaled Fluticasone Propionate in the Treatment of Adolescents and Adults (12 Years of Age and Older) With Asthma. (AUSTRI). ClinicalTrials.gov 2012 (accessed June 2012).
32. Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM, SMART Study Group. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 2006;129(1):15-26.
33. Ni Chroinin M, Lasserson Toby J, Greenstone I, Ducharme Francine M. Addition of long-acting beta-agonists to inhaled corticosteroids for chronic asthma in children. Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd, 2009, issue 3. [DOI: 10.1002/14651858.CD007949]
34. Phillips GD, Finnerty JP, Holgate ST. Comparative protective effect of the inhaled beta-2-agonist salbutamol (albuterol) on bronchoconstriction provoked by histamine, methacholine, and adenosine 5'-monophosphate in asthma. Journal of Allergy and Clinical Immunology 1990;85(4):755-62.
35. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011.
36. Salpeter SR, Buckley NS, Ormiston TM, Salpeter EE. Meta-analysis: effect of long-acting beta-agonists on severe asthma exacerbations and asthma-related deaths. Annals of Internal Medicine 2006;144(12):904-12.
37. Senn SJ, Lillienthal J, Patalano F, Till D. An incomplete blocks cross-over in asthma: a case study in collaboration. In: Vollmar J, Hothorn LA editor(s). Cross-over Clinical Trials. Stuttgart: Fischer, 1997:3-26.
38. Shea B, Grimshaw J, Wells G, Boers M, Andersson N, Hamel C, et al.Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. BMC Medical Research Methodology 2007;7:10. [DOI: 10.1186/1471-2288-7-10]
39. Scottish Intercollegiate Guidelines Network/British Thoracic Society. British guideline on the management of asthma: a national clinical guideline. Edinburgh: Scottish Intercollegiate Guidelines Network, 2008 (revised 2012).
40. Tattersfield AE. Current issues with beta2-adrenoceptor agonists: historical background. Clinical Reviews in Allergy and Immunology 2006;31(2-3):107-18.
41. Van Noord JA, Smeets JJ, Raaijmakers JAM, Bommer AM, Maesen FPV. Salmeterol versus formoterol in patients with moderately severe asthma: onset and duration of action. European Respiratory Journal 1996;9(8):1684-8.
42. Visual Rx. www.nntonline.net/visualrx/ Accessed June 2012.
43. Weinberger M, Abu-Hasan M. Life threatening asthma during treatment with salmeterol. The New England Journal of Medicine 2006;355:852-3.
44. Whittington CJ, Kendall T, Fonagy P, Cottrell D, Cotgrove A, Boddington E. Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data. Lancet 2004;363(9418):1341-5.